{
    "eid": "2-s2.0-85132582324",
    "title": "Incidence density and factors associated with peripheral neuropathy among women with breast cancer during taxane-based chemotherapy",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Multidisciplinary",
            "@code": "1000",
            "@abbrev": "MULT"
        }
    ],
    "keywords": [],
    "authors": [
        "Nida Rattanakrong",
        "Akkradate Siriphorn",
        "Sujitra Boonyong"
    ],
    "citedby-count": 4,
    "ref-count": 35,
    "ref-list": [
        "Taxane-induced peripheral neurotoxicity",
        "Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research",
        "Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis",
        "Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk",
        "Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update",
        "Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer",
        "Falls in older adults with cancer: a systematic review of prevalence, injurious falls, and impact on cancer treatment",
        "Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials",
        "Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study",
        "Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer",
        "Measures of disease frequency: prevalence and incidence",
        "The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20",
        "Chemotherapy-induced peripheral neuropathy (CIPN): a cross-sectional study in cancer patients",
        "Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy",
        "Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors",
        "Model building strategy for logistic regression: purposeful selection",
        "The impact of confounder selection criteria on effect estimation",
        "Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)",
        "Mitotoxicity in distal symmetrical sensory peripheral neuropathies",
        "Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction",
        "Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat",
        "Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840",
        "Weekly paclitaxel in the adjuvant treatment of breast cancer",
        "Peripheral nerve damage associated with administration of taxanes in patients with cancer",
        "Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives",
        "Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer",
        "Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools",
        "Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials",
        "Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy",
        "Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)",
        "Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN)",
        "Aging and muscle: a neuron's perspective",
        "Influence of aging on peripheral nerve function and regeneration",
        "Neurotoxicity of Taxol",
        "Report of the national institute on aging task force on comorbidity"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022464",
            "affilname": "Chulabhorn Royal Academy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022464",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University"
    ]
}